2024
The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells
Liao X, Li W, Zhou H, Rajendran B, Li A, Ren J, Luan Y, Calderwood D, Turk B, Tang W, Liu Y, Wu D. The CUL5 E3 ligase complex negatively regulates central signaling pathways in CD8+ T cells. Nature Communications 2024, 15: 603. PMID: 38242867, PMCID: PMC10798966, DOI: 10.1038/s41467-024-44885-0.Peer-Reviewed Original ResearchConceptsCD8+ T cellsT cellsCancer immunotherapyMouse CD8+ T cellsAnti-tumor immunityTumor growth inhibition abilityAnti-tumor effectsInhibition of neddylationCD8Effector functionsTCR stimulationIL2 signalingCentral signaling pathwaysCore signaling pathwaysEffector activityNegative regulatory mechanismsTranslational implicationsImmunotherapyGrowth inhibition abilityCytokine signalingTCRProteomic alterationsSignaling pathwayCancerCRISPR-based screens
2022
Development of patient derived organoids for cancer drug screening applications
Baskar G, Palaniyandi T, Viswanathan S, Rajendran B, Ravi M, Sivaji A. Development of patient derived organoids for cancer drug screening applications. Acta Histochemica 2022, 124: 151895. PMID: 35486967, DOI: 10.1016/j.acthis.2022.151895.Peer-Reviewed Original ResearchConceptsPre-clinical modelsEx vivo tissue cultureDevelopment of patientsCancer researchStem cellsVivo tissue culturePatient responseAbnormal cell growthProgenitor cellsHigh-throughput drug screeningVivo propertiesOrganoidsHuman organoidsPluripotent stem cellsCell growthDrug screening applicationsDrug screeningThroughput drug screeningEmbryonic stem cellsTissueCellsTissue cultureEffective recapitulationPatientsClinic
2021
Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform
Xing F, Liu Y, Huang S, Lyu X, Su S, Chan U, Wu P, Yan Y, Ai N, Li J, Zhao M, Rajendran B, Liu J, Shao F, Sun H, Choi T, Zhu W, Luo G, Liu S, Xu D, Chan K, Zhao Q, Miao K, Luo K, Ge W, Xu X, Wang G, Liu T, Deng C. Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform. Theranostics 2021, 11: 9415-9430. PMID: 34646378, PMCID: PMC8490519, DOI: 10.7150/thno.59533.Peer-Reviewed Original ResearchConceptsAnti-cancer therapyNew pre-clinical modelsDay of surgeryPre-clinical modelsRNA sequence analysisHigh-efficacy drugsAnti-cancer drug efficacyPD-1PD-L1Personalized medicineBlockade assayAnti-cancer drug discoveryImmune componentsOriginal tumorAutofluorescence featuresDrug efficacyHistological analysisPrecision anti-cancer therapyCancer treatmentDrug responseHigh-throughput drug screeningDrug discoveryTherapyEfficacyCell-based high-throughput drug screening
2020
Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations
Bhaskaran S, Huang T, Rajendran B, Guo M, Luo J, Qin Z, Zhao B, Chian J, Li S, Wang S. Ethnic-specific BRCA1/2 variation within Asia population: evidence from over 78 000 cancer and 40 000 non-cancer cases of Indian, Chinese, Korean and Japanese populations. Journal Of Medical Genetics 2020, 58: 752-759. PMID: 32963034, DOI: 10.1136/jmedgenet-2020-107299.Peer-Reviewed Original Research